ASCO GU 2019 Prostate Cancer - Results from #20

Viewing 21-40 of 47 articles

ASCO GU 2019: Efficacy and Safety Data of the ARAMIS Study, Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Patients

ASCO GU 2019: Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer

ASCO GU 2019: LATITUDE Study - Final Analysis of Phase III Study in Patients with Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer

ASCO GU 2019: A Phase II, Open-label, Multi-arm Study of TAS-115 for Castration-resistant Prostate Cancer Patients with Bone Metastases

ASCO GU 2019: A Randomized Trial Comparing Fluorocholine-PET/CT with Conventional Imaging in Prostate Cancer

ASCO GU 2019: Discussion on: The ARAMIS Trial, the Final Analysis of LATITUDE Study, and the ARCHES Trial

ASCO GU 2019: Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: ARCHES Trial-Phase 3 Study of ADT with Enzalutamide in mHSPC

ASCO GU 2019: Keynote-365: Pembrolizumab Plus Olaparib in Docetaxel Pretreated Patients with Metastatic Castrate-resistant Prostate Cancer

ASCO GU 2019: Final Analysis of LATITUDE, A Phase III in Patients with Newly Diagnosed High-risk Metastatic Castration-naïve Prostate Cancer

ASCO GU 2019: Skeletal Related Events in CTRIAL-IE 13-21: Radium-223 in Combination with Enzalutamide for Patients with mCRPC

ASCO GU 2019: Phase II Study of Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer and Biallelic DNA-Repair Gene Defects : Preliminary Results of GALAHAD

ASCO GU 2019: Updated Analysis of Progression-Free Survival with First Subsequent Therapy and Safety in the SPARTAN Study of Apalutamide in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First Line Chemotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer: CHEIRON Study

ASCO GU 2019: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: DORA

ASCO GU 2019: Cost-Effectiveness of Metastasis-Directed Therapy in the Setting of Oligometastatic Hormone-Sensitive Prostate Cancer

ASCO GU 2019: Quality of Life-Focused Decision-Making for Castrate-Sensitive Prostate Cancer

ASCO GU 2019: Discussion on: Results of Checkmate 650 and Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in mCRPC Trials

ASCO GU 2019: Initial Results from Checkmate 650, a Phase II Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: Assessment of Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in Phase II Trials for Metastatic Castrate-Resistant Prostate Cancer

1
2
3